Tri-Lo-Sprintec Shortage Update: What Patients Need to Know in 2026

If you've been struggling to find Tri-Lo-Sprintec 28 Day at your pharmacy, you're probably wondering whether there's an official shortage. The short answer: no — but there's more to the story. Here's the complete 2026 update on Tri-Lo-Sprintec availability.

Official FDA Shortage Status (2026)

As of 2026, Tri-Lo-Sprintec 28 Day (norgestimate/ethinyl estradiol triphasic, low-dose) is NOT listed on the FDA's official drug shortage database. This means there is no formal, nationwide shortage of the active pharmaceutical ingredients or the finished dosage form.

Multiple generic manufacturers continue to produce norgestimate/ethinyl estradiol triphasic low-dose tablets under various brand names. National supply is considered stable.

Why Are Some Patients Still Having Trouble Finding It?

Despite no official shortage, patients still report difficulty finding Tri-Lo-Sprintec for several reasons:

• Pharmacy-level stockouts: Individual pharmacies may run out of their preferred brand, even when other equivalent brands are available at other locations.
• Brand discontinuation confusion: Ortho Tri-Cyclen Lo (the original brand-name product) was voluntarily discontinued by Janssen Pharmaceuticals when generics captured the market. Some prescriptions still written for the discontinued brand create filling delays.
• DAW restrictions: Prescriptions with a "dispense as written" note prevent pharmacists from substituting equivalent generics, causing delays when one specific brand is out of stock.
• Distribution lags: Supply chain and ordering schedules can create temporary gaps at specific pharmacies, even when overall national supply is adequate.

Historical Context: Has Tri-Lo-Sprintec Ever Been in Official Shortage?

The norgestimate/ethinyl estradiol market is mature and well-established. Since multiple generic manufacturers produce these tablets, a nationwide shortage affecting all manufacturers simultaneously would be unusual. The primary access issues have historically been:

• 2017–2018: Janssen discontinued Ortho Tri-Cyclen Lo; patients initially struggled to find it before generics became widely distributed
• 2020–2021: COVID-19 supply chain disruptions affected many generic medications, including some oral contraceptives, though no formal shortage was declared
• 2024–2026: No FDA-declared shortage; stable supply from multiple generic manufacturers

What Patients Can Do Right Now

The most effective strategies for patients experiencing access issues in 2026:

1. Accept equivalent generics. Ask your pharmacist if Tri-Lo-Estarylla, Tri-Lo-Mili, Tri-Lo-Marzia, or Tri-Vylibra Lo is in stock. All are FDA AB-rated equivalents.
2. Use medfinder. medfinder calls pharmacies near you and texts you results — no need to call around yourself.
3. Update your prescription. Ask your prescriber to write for norgestimate/ethinyl estradiol triphasic low-dose generically, without a DAW restriction, and for a 90-day supply if possible.
4. Consider mail-order. Mail-order pharmacies carry larger inventories and are less susceptible to local stockouts.

For a deeper dive into why access issues occur, see: Why Is Tri-Lo-Sprintec 28 Day So Hard to Find? [Explained for 2026].

If no equivalent is available in your area: Alternatives to Tri-Lo-Sprintec 28 Day If You Can't Fill Your Prescription.